<DOC>
	<DOCNO>NCT01817439</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) remain significant contributor cardiovascular morbidity . Amiodarone potent antiarrhythmic drug ; however , patient receive IV amiodarone high risk phlebitis . Phlebitis may lead infection , additional medical intervention , delay treatment , prolonged hospitalization . Therefore , examine new therapy approach , aim reduce incidence phlebitis valuable clinical research goal . Aim : To evaluate safety efficacy oral versus intravenous ( IV ) Amiodarone treatment AF recent onset ( duration &lt; 48 h ) .</brief_summary>
	<brief_title>Safety Efficacy Oral Versus Intravenous Amiodarone Treatment AF</brief_title>
	<detailed_description>Atrial fibrillation ( AF ) common heart rhythm abnormality worldwide . Three therapeutic goal consider patient : Rate control , maintenance sinus rhythm prevention thromboembolism . In manage AF , numerous antiarrhythmic drug use . Intravenous amiodarone class III antiarrhythmic agent report safe effective various clinical setting , without associate increase mortality rate . In case , method administration via peripheral infusion . Phlebitis common complication peripheral infusion amiodarone . Phlebitis adversely affect patient care ; may interfere continue infusion amiodarone , necessitate insertion another peripheral intravenous central catheter , extend hospitalization . Furthermore , patient develop phlebitis , experience pain , swell , inflammation . Phlebitis prevent oral administration . The goal propose study evaluate incidence rate phlebitis follow IV administration amiodarone investigate whether oral administration amiodarone patient recent onset AF ( duration &lt; 48 h ) , safe , efficient , IV administration drug ICCU ICU setting .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Over 18 year age , Patients admit ICCU / ICU ward Patients recent onset atrial fibrillation ( duration &lt; 48h ) . Age &lt; 18 year Baseline systolic blood pressure &lt; 100 mm/hg Known thyroid disease Serum potassium &lt; 3.5 mmol/l Pretreatment amiodarone Pregnant lactate woman . Participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>oral Amiodarone</keyword>
	<keyword>IV Amiodarone</keyword>
	<keyword>phlebitis</keyword>
	<keyword>thrombophlebitis</keyword>
	<keyword>adverse event</keyword>
</DOC>